Clinical Trial Update: Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation trial of teclistamab (Tecvayli), a humanized BCMA-CD3 bispecific antibody, in relapsed or refractory multiple myeloma; the study status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Hematological Malignancies | Phase 1 | Status: ACTIVE_NOT_RECRUITING